Neurofibromatosis Type 1 Clinical Trial
Official title:
Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden
The purpose of this study is to identify tumor biomarkers in individuals with Neurofibromatosis type 1 (NF1). Biomarkers are signals that the investigator can measure that tell us about a process such as progress of a disease or treatment. Individuals with this diagnosis are at an elevated risk of developing a type of tumor called a plexiform neurofibroma. Currently, detecting the risk factors of these tumors in children is difficult and requires whole body imaging. The NF1 team at Lurie Children's established a way of using blood plasma in mice with neurofibromatosis type 1 to identify biomarkers that might signal the presence of tumors in people with NF1. This study is an effort to create biomarker profiles of patients with NF1 with known tumors. The study team will utilize whole-body MRI and mass spectrometry (a method for identifying unknown compounds and the properties of molecules). The ultimate goal of this study is to better understand the tumor biomarkers in patients with NF1.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | June 2026 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Individuals with known diagnosis of neurofibromatosis type 1 (NF1) Exclusion Criteria: 1. Patient does not meet NF1 diagnostic criteria 2. Mosaic NF1 individuals 3. Pregnant at Screening 4. Patients who do not have the ability/capacity to undergo the informed consent process OR whose parent/legal guardian is unable to undergo the informed consent process. |
Country | Name | City | State |
---|---|---|---|
United States | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Ann & Robert H Lurie Children's Hospital of Chicago | Children's Hospital Medical Center, Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000 Jan;5(1):189-95. doi: 10.1016/s1097-2765(00)80415-3. — View Citation
Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996 Feb;12(2):144-8. doi: 10.1038/ng0296-144. — View Citation
Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal. 2015 Sep 10;113:108-20. doi: 10.1016/j.jpba.2014.12.017. Epub 2014 Dec 25. — View Citation
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016 Dec 29;375(26):2550-2560. doi: 10.1056/NEJMoa1605943. — View Citation
Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, Korf BR, Babovic-Vuksanovic D, Packer RJ, Belasco J, Goldman S, Jakacki R, Kieran M, Steinberg SM, Widemann BC. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007 Feb 27;68(9):643-7. doi: 10.1212/01.wnl.0000250332.89420.e6. Epub 2007 Jan 10. — View Citation
Fletcher JS, Pundavela J, Ratner N. After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation. Neurooncol Adv. 2019 Nov 22;2(Suppl 1):i23-i32. doi: 10.1093/noajnl/vdz045. eCollection 2020 Jul. — View Citation
Fletcher JS, Springer MG, Choi K, Jousma E, Rizvi TA, Dombi E, Kim MO, Wu J, Ratner N. STAT3 inhibition reduces macrophage number and tumor growth in neurofibroma. Oncogene. 2019 Apr;38(15):2876-2884. doi: 10.1038/s41388-018-0600-x. Epub 2018 Dec 12. — View Citation
Fletcher JS, Wu J, Jessen WJ, Pundavela J, Miller JA, Dombi E, Kim MO, Rizvi TA, Chetal K, Salomonis N, Ratner N. Cxcr3-expressing leukocytes are necessary for neurofibroma formation in mice. JCI Insight. 2019 Feb 7;4(3):e98601. doi: 10.1172/jci.insight.98601. — View Citation
Grissa D, Petera M, Brandolini M, Napoli A, Comte B, Pujos-Guillot E. Feature Selection Methods for Early Predictive Biomarker Discovery Using Untargeted Metabolomic Data. Front Mol Biosci. 2016 Jul 8;3:30. doi: 10.3389/fmolb.2016.00030. eCollection 2016. — View Citation
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020 Apr 9;382(15):1430-1442. doi: 10.1056/NEJMoa1912735. Epub 2020 Mar 18. Erratum In: N Engl J Med. 2020 Sep 24;383(13):1290. — View Citation
Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013 Jan;123(1):340-7. doi: 10.1172/JCI60578. Epub 2012 Dec 10. — View Citation
Johnson CH, Ivanisevic J, Benton HP, Siuzdak G. Bioinformatics: the next frontier of metabolomics. Anal Chem. 2015 Jan 6;87(1):147-56. doi: 10.1021/ac5040693. Epub 2014 Nov 20. No abstract available. — View Citation
Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer. 2015 Oct;62(10):1709-16. doi: 10.1002/pbc.25546. Epub 2015 Apr 22. — View Citation
Largaespada DA, Brannan CI, Jenkins NA, Copeland NG. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996 Feb;12(2):137-43. doi: 10.1038/ng0296-137. — View Citation
Le LQ, Parada LF. Tumor microenvironment and neurofibromatosis type I: connecting the GAPs. Oncogene. 2007 Jul 12;26(32):4609-16. doi: 10.1038/sj.onc.1210261. Epub 2007 Feb 12. — View Citation
McCormick F. Ras signaling and NF1. Curr Opin Genet Dev. 1995 Feb;5(1):51-5. doi: 10.1016/s0959-437x(95)90053-5. — View Citation
Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013 Jan;125(1):159-68. doi: 10.1007/s00401-012-1056-7. Epub 2012 Oct 26. — View Citation
Prada CE, Rangwala FA, Martin LJ, Lovell AM, Saal HM, Schorry EK, Hopkin RJ. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012 Mar;160(3):461-7. doi: 10.1016/j.jpeds.2011.08.051. Epub 2011 Oct 11. — View Citation
Ratner N, Miller SJ. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015 May;15(5):290-301. doi: 10.1038/nrc3911. Epub 2015 Apr 16. — View Citation
Redrup MJ, Igarashi H, Schaefgen J, Lin J, Geisler L, Ben M'Barek M, Ramachandran S, Cardoso T, Hillewaert V. Sample Management: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 2016 Mar;18(2):290-3. doi: 10.1208/s12248-016-9869-2. Epub 2016 Jan 28. — View Citation
Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997 Nov 30;16(22):2529-42. doi: 10.1002/(sici)1097-0258(19971130)16:223.0.co;2-j. — View Citation
Setchell KD, Nardi E, Battezzati PM, Asciutti S, Castellani D, Perriello G, Clerici C. Novel soy germ pasta enriched in isoflavones ameliorates gastroparesis in type 2 diabetes: a pilot study. Diabetes Care. 2013 Nov;36(11):3495-7. doi: 10.2337/dc12-1615. Epub 2013 Jul 8. — View Citation
van de Merbel N, Savoie N, Yadav M, Ohtsu Y, White J, Riccio MF, Dong K, de Vries R, Diancin J. Stability: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 2014 May;16(3):392-9. doi: 10.1208/s12248-014-9573-z. Epub 2014 Feb 19. — View Citation
Watanabe M, Roth TL, Bauer SJ, Lane A, Romick-Rosendale LE. Feasibility Study of NMR Based Serum Metabolomic Profiling to Animal Health Monitoring: A Case Study on Iron Storage Disease in Captive Sumatran Rhinoceros (Dicerorhinus sumatrensis). PLoS One. 2016 May 27;11(5):e0156318. doi: 10.1371/journal.pone.0156318. eCollection 2016. — View Citation
Weiss B, Plotkin S, Widemann B, Tonsgard J, Blakeley J, Allen J, Schorry E, Korf B, Rosser T, Goldman S, Vinks A, Cutter G, Dombi E, Ratner N, Packer R, Fisher M. NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY. Neuro Oncol. 2018 Jun;20(Suppl 2):i143. doi: 10.1093/neuonc/noy059.514. Epub 2018 Jun 22. PMCID: PMC6012484.
Wu J, Dombi E, Jousma E, Scott Dunn R, Lindquist D, Schnell BM, Kim MO, Kim A, Widemann BC, Cripe TP, Ratner N. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. 2012 Feb;58(2):173-80. doi: 10.1002/pbc.23015. Epub 2011 Feb 11. — View Citation
Wu J, Williams JP, Rizvi TA, Kordich JJ, Witte D, Meijer D, Stemmer-Rachamimov AO, Cancelas JA, Ratner N. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell. 2008 Feb;13(2):105-16. doi: 10.1016/j.ccr.2007.12.027. — View Citation
* Note: There are 27 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine if glucosylceramide (GC) and lactosylceramide (LC) species levels correlate with tumor burden in patients with NF1 | The investigator and team will collect blood samples from individuals with NF1 stratified plexiform tumor (PNF) burden (none, small, intermediate, and large) versus age and sex matched healthy control. | 1 year | |
Primary | Test if tumor burden correlates with GC and LC signature in individuals with NF1 who are undergoing clinical treatment with MEK inhibitors | The investigator and team will enroll 20 individuals with NF1 and inoperable PNFs in treatment with MEK inhibitors to correlate biomarker with tumor burden changes with therapy. | 1 year | |
Primary | Assemble a longitudinal cohort of individuals with NF1 with plexiform neurofibromas (n=100) for deep phenotyping and tumor burden response to MEK inhibitors | Whole-body MRI at baseline and at time of annual visit (9-to-18-month intervals) will be used to deeply phenotype individuals based on tumor burden and tumor volume. Individuals will undergo plasma collection and clinical history assessment (medications, diet log, supplements, and anthropometric measurements) at each visit. For patients undergoing treatment with MEK inhibitors, a sample prior to treatment will be collected during this study. | 1 year | |
Primary | Determine if glucosylceramide (GC) and lactosylceramide (LC) signature correlates with plexiform neurofibroma burden change in longitudinal cohort of 100 individuals with PNFs | The investigator and team will test GC/LC levels using validated mass spectrometry target method for quantification of these biomarkers. | 1 year | |
Primary | Tumor volumetric analysis will be performed to correlate with GC/LC monitoring biomarker signature | GC/LC biomarker thresholds (cut-off) will be refined to evaluate predictive ability to identify individuals with large tumor burden. Tumor burden will be measured from whole-body MRI analysis with post-imaging processing software. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03190915 -
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT03326388 -
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01218139 -
Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients
|
N/A | |
Recruiting |
NCT05149469 -
Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
|
||
Not yet recruiting |
NCT02505412 -
Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
|
N/A | |
Terminated |
NCT02256124 -
Effect of Lamotrigine on Cognition in NF1
|
Phase 2/Phase 3 | |
Completed |
NCT01707836 -
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
|
N/A | |
Active, not recruiting |
NCT01218152 -
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
|
N/A | |
Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 | |
Recruiting |
NCT05186870 -
Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
|
||
Active, not recruiting |
NCT03231306 -
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
|
Phase 2 | |
Withdrawn |
NCT03332030 -
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
|
||
Recruiting |
NCT02964884 -
Interventions for Reading Disabilities in NF1
|
Phase 2 | |
Recruiting |
NCT05388370 -
PASS of Paediatric Patients Initiating Selumetinib
|
||
Recruiting |
NCT02777775 -
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
|
||
Completed |
NCT02944032 -
Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT01851135 -
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT01410006 -
Neurofibromatosis Type 1 Patient Registry
|
N/A |